The global traumatic brain injuries assessment and management devices market accounted for USD 3.49 billion in 2023 and is expected to reach at USD 7.88 billion by 2034 with a CAGR of 7.68% during the forecast period 2024-2034. Growing incidence of traumatic brain injuries (TBIs), increasing demand for minimally invasive procedures., rising awareness about brain injury treatment, surge in adoption of technologically advanced products, growing supportive government policies, increased investment from major market players, rising prevalence of sports injuries, falls, gunshot wounds, road traffic accidents, & domestic violence, surge in demand for minimally invasive neuro procedures, and uptick in approvals for advanced devices for assessing and managing traumatic brain injuries are some of the key factors boosting the market growth.
Uptick in approvals for advanced devices for assessing and managing traumatic brain injuries is predicted to boost the market growth during the forecast period. Traumatic Brain Injury (TBI) occurs when the brain's normal function is disrupted due to impact from a blow, jolt, or penetrating injury to the head. Symptoms of TBI can range from minor to severe, depending on the degree of brain damage. Mild cases may lead to temporary changes in mental state or consciousness, while severe cases can result in extended periods of unconsciousness, coma, or fatality. For instance, in March 2023, Abbott disclosed that it obtained approval from the USFDA for Alinity I, a laboratory device designed for conducting blood tests related to traumatic brain injury (TBI). This instrument is equipped to swiftly administer the i-STAT TBI plasma test, delivering precise data for the rapid assessment of mild TBI patients. The regulatory clearance has bolstered Abbott's research and development capabilities and bolstered its position in the market.
By device, imaging devices was the highest revenue-grossing segment in the global traumatic brain injuries assessment and management devices market in 2023 owing to the heightened sensitivity of imaging devices is expanding their usage in diagnosing & staging neurological diseases, notably traumatic brain injuries (TBIs), and increasing array of advanced devices being introduced. For instance, in March 2022, The Swift Ray 1, a novel hardware innovation from Swift Medical Inc., wirelessly connects to a smartphone camera. This device transforms wound care technology by capturing thorough clinical data, significantly improving the evaluation and treatment monitoring of wounds and various skin conditions. Compact in design, the Swift Ray 1 conveniently fits in the hand of clinicians or patients, enabling easy and portable medical imaging. Additionally, monitoring devices is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for minimally invasive procedures, heightened awareness about related devices, and surge in enhancements in healthcare facilities.
By technique, intracranial pressure monitoring was the highest revenue-grossing segment in the global traumatic brain injuries assessment and management devices market in 2023 owing to the benefits of intracranial pressure monitoring, rising incidence of traumatic brain injury (TBI) cases, expanding regulatory approvals. For instance, in October 2023, bioMérieux, a global leader in in vitro diagnostics, has obtained CE-marking for VIDAS TBI (GFAP, UCH-L1), a blood test designed to aid in evaluating individuals with mild traumatic brain injury (mTBI). This test relies on a distinctive blend of brain biomarkers, including GFAP and UCH-L1. Additionally, partial pressure of oxygen in the brain tissue (pBrO2) is predicted to grow at the fastest CAGR during the forecast period owing to the continuous monitoring of pBrO2 offers timely insights into cerebral oxygen demand for individuals with traumatic brain injury (TBI). These monitoring systems track the partial pressure of oxygen in brain tissue continuously, offering early detection of hypoxic occurrences.
By end-user, hospital was the highest revenue-grossing segment in the global traumatic brain injuries assessment and management devices market in 2023 owing to the rise in the number of brain surgeries conducted in hospitals, increase in the number of patients with traumatic brain injuries (TBIs), growing utilization of advanced technological devices by hospitals, and an uptick in regulatory authorizations. For instance, in August 2022, BrainScope Company Inc. introduced an FDA-cleared, handheld Class 2 medical device utilizing artificial intelligence and machine learning to detect objective biomarkers of both structural (intracranial hemorrhage) and functional (concussion) brain injuries in individuals suspected of having mild traumatic brain injury (mTBI). Furthermore, it obtained a contract for Innovative Technology from Vizient, Inc., the biggest member-driven healthcare performance improvement organization in the country. Additionally, others is expected to grow at the fastest CAGR during the forecast period. Emergency clinics and Ambulatory Surgical Centers (ASCs) provide several benefits compared to hospitals, including shorter procedure durations and the option for same-day discharge. They also offer cost-effective solutions and continuous advancements in minimally invasive surgical methods, resulting in reduced procedure times.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of established healthcare facilities, growing governmental efforts, heightened awareness campaigns on brain injuries, elevated prevalence of traumatic brain injuries (TBIs), and increased investment from major industry players. For instance, in December 2022, The Defense Health Agency (DHA) awarded General Dynamics Information Technology (GDIT), a division of General Dynamics, an $84 million contract to provide assistance to the Traumatic Brain Injury Center of Excellence (TBICoE). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the expanding elderly population, rise in individuals affected by traumatic brain injuries (TBIs), escalating prevalence of road accidents & violence, growing affordability among patients, and upsurge in partnerships among industry participants. For instance, in October 2023, GE Healthcare Technologies Inc has revealed a partnership with Imeka aimed at enhancing MRI capabilities for brain imaging and advancing precision medicine in brain health. Through this collaboration, GE Healthcare Technologies Inc has integrated Imeka's neuroimaging technology, the ANIE biomarker platform, which offers extensive applications in both research and clinical care settings for various central nervous system diseases and disorders, including traumatic brain injury, Parkinson's disease, Alzheimer's disease, and multiple sclerosis.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Uptick in approvals for advanced devices for assessing and managing traumatic brain injuries is predicted to boost the market growth during the forecast period. Traumatic Brain Injury (TBI) occurs when the brain's normal function is disrupted due to impact from a blow, jolt, or penetrating injury to the head. Symptoms of TBI can range from minor to severe, depending on the degree of brain damage. Mild cases may lead to temporary changes in mental state or consciousness, while severe cases can result in extended periods of unconsciousness, coma, or fatality. For instance, in March 2023, Abbott disclosed that it obtained approval from the USFDA for Alinity I, a laboratory device designed for conducting blood tests related to traumatic brain injury (TBI). This instrument is equipped to swiftly administer the i-STAT TBI plasma test, delivering precise data for the rapid assessment of mild TBI patients. The regulatory clearance has bolstered Abbott's research and development capabilities and bolstered its position in the market.
By device, imaging devices was the highest revenue-grossing segment in the global traumatic brain injuries assessment and management devices market in 2023 owing to the heightened sensitivity of imaging devices is expanding their usage in diagnosing & staging neurological diseases, notably traumatic brain injuries (TBIs), and increasing array of advanced devices being introduced. For instance, in March 2022, The Swift Ray 1, a novel hardware innovation from Swift Medical Inc., wirelessly connects to a smartphone camera. This device transforms wound care technology by capturing thorough clinical data, significantly improving the evaluation and treatment monitoring of wounds and various skin conditions. Compact in design, the Swift Ray 1 conveniently fits in the hand of clinicians or patients, enabling easy and portable medical imaging. Additionally, monitoring devices is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for minimally invasive procedures, heightened awareness about related devices, and surge in enhancements in healthcare facilities.
By technique, intracranial pressure monitoring was the highest revenue-grossing segment in the global traumatic brain injuries assessment and management devices market in 2023 owing to the benefits of intracranial pressure monitoring, rising incidence of traumatic brain injury (TBI) cases, expanding regulatory approvals. For instance, in October 2023, bioMérieux, a global leader in in vitro diagnostics, has obtained CE-marking for VIDAS TBI (GFAP, UCH-L1), a blood test designed to aid in evaluating individuals with mild traumatic brain injury (mTBI). This test relies on a distinctive blend of brain biomarkers, including GFAP and UCH-L1. Additionally, partial pressure of oxygen in the brain tissue (pBrO2) is predicted to grow at the fastest CAGR during the forecast period owing to the continuous monitoring of pBrO2 offers timely insights into cerebral oxygen demand for individuals with traumatic brain injury (TBI). These monitoring systems track the partial pressure of oxygen in brain tissue continuously, offering early detection of hypoxic occurrences.
By end-user, hospital was the highest revenue-grossing segment in the global traumatic brain injuries assessment and management devices market in 2023 owing to the rise in the number of brain surgeries conducted in hospitals, increase in the number of patients with traumatic brain injuries (TBIs), growing utilization of advanced technological devices by hospitals, and an uptick in regulatory authorizations. For instance, in August 2022, BrainScope Company Inc. introduced an FDA-cleared, handheld Class 2 medical device utilizing artificial intelligence and machine learning to detect objective biomarkers of both structural (intracranial hemorrhage) and functional (concussion) brain injuries in individuals suspected of having mild traumatic brain injury (mTBI). Furthermore, it obtained a contract for Innovative Technology from Vizient, Inc., the biggest member-driven healthcare performance improvement organization in the country. Additionally, others is expected to grow at the fastest CAGR during the forecast period. Emergency clinics and Ambulatory Surgical Centers (ASCs) provide several benefits compared to hospitals, including shorter procedure durations and the option for same-day discharge. They also offer cost-effective solutions and continuous advancements in minimally invasive surgical methods, resulting in reduced procedure times.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of established healthcare facilities, growing governmental efforts, heightened awareness campaigns on brain injuries, elevated prevalence of traumatic brain injuries (TBIs), and increased investment from major industry players. For instance, in December 2022, The Defense Health Agency (DHA) awarded General Dynamics Information Technology (GDIT), a division of General Dynamics, an $84 million contract to provide assistance to the Traumatic Brain Injury Center of Excellence (TBICoE). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the expanding elderly population, rise in individuals affected by traumatic brain injuries (TBIs), escalating prevalence of road accidents & violence, growing affordability among patients, and upsurge in partnerships among industry participants. For instance, in October 2023, GE Healthcare Technologies Inc has revealed a partnership with Imeka aimed at enhancing MRI capabilities for brain imaging and advancing precision medicine in brain health. Through this collaboration, GE Healthcare Technologies Inc has integrated Imeka's neuroimaging technology, the ANIE biomarker platform, which offers extensive applications in both research and clinical care settings for various central nervous system diseases and disorders, including traumatic brain injury, Parkinson's disease, Alzheimer's disease, and multiple sclerosis.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Device, Technique, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Traumatic Brain Injuries Assessment And Management Devices Market Report 2023 - 2034
Traumatic Brain Injuries Assessment And Management Devices Market Analysis & Forecast by Device 2023 - 2034 (Revenue USD Bn)
- Monitoring Devices
- Imaging Devices
- X-Ray
- Computed Tomography
- Magnetic Resonance Imaging (MRI) Devices
Traumatic Brain Injuries Assessment And Management Devices Market Analysis & Forecast by Technique 2023 - 2034 (Revenue USD Bn)
- Partial Pressure Of Oxygen In Brain Tissue (pBrO2)
- Intracranial Pressure Monitoring
Traumatic Brain Injuries Assessment And Management Devices Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Diagnostic Centers
- Others
- Ambulatory Surgical Centers (ASCs)
- Emergency Clinics
- Research Centers
Traumatic Brain Injuries Assessment And Management Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Traumatic Brain Injuries Assessment And Management Devices Market: Device Estimates & Trend Analysis
8. Traumatic Brain Injuries Assessment And Management Devices Market: Technique Estimates & Trend Analysis
9. Traumatic Brain Injuries Assessment And Management Devices Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Traumatic Brain Injuries Assessment And Management Devices Market
12. Europe Global Traumatic Brain Injuries Assessment And Management Devices Market
13. Asia Pacific Global Traumatic Brain Injuries Assessment And Management Devices Market
14. Latin America Global Traumatic Brain Injuries Assessment And Management Devices Market
15. MEA Global Traumatic Brain Injuries Assessment And Management Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Compumedics Ltd.
- BioDirection Inc.
- InfraScan Inc.
- Raumedic AG
- Integra Lifesciences
- Oculogica
- Nihon Kohden Corp.
